Avista Pharma Appoints Eric Evans as CFO
Avista Pharma has appointed Eric Evans as CFO.
On Aug. 29, 2017, Avista Pharma appointed Eric Evans as CFO effective Aug. 28, 2017. Evans will oversee the company’s finance, purchasing and information technology operations. With more than 30 years of experience, Mr. Evans has held leadership roles in companies across the pharmaceutical and contract service sectors, including CFO of Mayne Pharma, AAIPharma Services, and Patheon. He also held positions as vice president and controller for Novartis and Sandoz.
“Eric has a proven track record of providing leadership in financial and operational strategies in growth organizations,” said Patrick Walsh, CEO of Avista Pharma, in a company press release. “His experience will ensure continued success for the company and our clients, and I am delighted to be working with him again.”
Source: Avista Pharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
